Published in Int J Gynecol Cancer on June 01, 2012
Shikonin-loaded antibody-armed nanoparticles for targeted therapy of ovarian cancer. Int J Nanomedicine (2014) 0.88
Cytokine use and survival in the first-line treatment of ovarian cancer: a Gynecologic Oncology Group Study. Gynecol Oncol (2012) 0.79
Avastin doesn't blind people, people blind people. Am J Ophthalmol (2012) 3.15
Seroprevalence of Chikungunya virus infection on Grande Comore Island, union of the Comoros, 2005. Am J Trop Med Hyg (2007) 2.09
Hepatitis C infection in African Americans: its natural history and histological progression. Am J Gastroenterol (2002) 2.09
When chronic conditions become acute: prevention and control of chronic diseases and adverse health outcomes during natural disasters. Prev Chronic Dis (2005) 2.03
Apigenin inhibits VEGF and HIF-1 expression via PI3K/AKT/p70S6K1 and HDM2/p53 pathways. FASEB J (2005) 1.56
Lynch syndrome in women less than 50 years of age with endometrial cancer. Obstet Gynecol (2008) 1.54
Entomologic investigations of a chikungunya virus epidemic in the Union of the Comoros, 2005. Am J Trop Med Hyg (2008) 1.48
Excision repair cross complementing-group 1: gene expression and platinum resistance. Int J Mol Med (2004) 1.38
Attenuating astrocyte activation accelerates plaque pathogenesis in APP/PS1 mice. FASEB J (2012) 1.28
Molecular basis of cellular response to cisplatin chemotherapy in non-small cell lung cancer (Review). Oncol Rep (2004) 1.27
In vitro combination characterization of the new anticancer plant drug beta-elemene with taxanes against human lung carcinoma. Int J Oncol (2007) 1.26
Correlation of serum VEGF levels with clinical stage, therapy efficacy, tumor metastasis and patient survival in ovarian cancer. Anticancer Res (2004) 1.24
Enhancing response rates in physician surveys: the limited utility of electronic options. Health Serv Res (2011) 1.22
Development of a federally funded demonstration colorectal cancer screening program. Prev Chronic Dis (2008) 1.19
Evidence-based choices of physicians: a comparative analysis of physicians participating in Internet CME and non-participants. BMC Med Educ (2010) 1.18
CD44+/CD24- ovarian cancer cells demonstrate cancer stem cell properties and correlate to survival. Clin Exp Metastasis (2012) 1.18
IgE food sensitization in infants with eczema attending a dermatology department. J Pediatr (2007) 1.11
beta-Elemene, a novel plant-derived antineoplastic agent, increases cisplatin chemosensitivity of lung tumor cells by triggering apoptosis. Oncol Rep (2009) 1.11
Susceptibility loci associated with specific and shared subtypes of lymphoid malignancies. PLoS Genet (2013) 1.10
Modulation of protein phosphatase 2A activity alters androgen-independent growth of prostate cancer cells: therapeutic implications. Mol Cancer Ther (2011) 1.10
Production of catalytically inactive BoNT/A1 holoprotein and comparison with BoNT/A1 subunit vaccines against toxin subtypes A1, A2, and A3. Vaccine (2009) 1.09
Prospective randomized clinical trial comparing patient-controlled intravenous analgesia with patient-controlled epidural analgesia after lumbar spinal fusion. Spine (Phila Pa 1976) (2003) 1.08
CHK2 kinase expression is down-regulated due to promoter methylation in non-small cell lung cancer. Mol Cancer (2004) 1.08
Re: Bilateral same-day intravitreal injections using a single vial and molecular bacterial screening for safety surveillance. Retina (2013) 1.06
Vaccination coverage survey versus administrative data in the assessment of mass yellow fever immunization in internally displaced persons--Liberia, 2004. Vaccine (2005) 1.05
Regional decline of an iconic amphibian associated with elevation, land-use change, and invasive species. Conserv Biol (2011) 1.04
Role of chemotherapy for patients with recurrent platinum-resistant advanced epithelial ovarian cancer: A cost-effectiveness analysis. Cancer (2006) 1.04
Late rapid deterioration after endoscopic third ventriculostomy: additional cases and review of the literature. J Neurosurg (2006) 1.03
Randomized pilot trial of a synbiotic dietary supplement in chronic HIV-1 infection. BMC Complement Altern Med (2012) 1.02
Neuro-optic cell apoptosis and microangiopathy in KKAY mouse retina. Int J Mol Med (2004) 1.02
Myb overexpression overrides androgen depletion-induced cell cycle arrest and apoptosis in prostate cancer cells, and confers aggressive malignant traits: potential role in castration resistance. Carcinogenesis (2012) 1.00
Effect of a low-allergen maternal diet on colic among breastfed infants: a randomized, controlled trial. Pediatrics (2005) 1.00
Neural signals of extinction in the inhibitory microcircuit of the ventral midbrain. Nat Neurosci (2012) 1.00
Antineoplastic effect of beta-elemene on prostate cancer cells and other types of solid tumour cells. J Pharm Pharmacol (2010) 1.00
Views of biobanking research among Alaska native people: the role of community context. Prog Community Health Partnersh (2012) 0.99
Risk factors for clinical failure in patients hospitalized with cellulitis and cutaneous abscess. J Infect (2012) 0.98
Application of enterococci antibiotic resistance patterns for contamination source identification at Huntington Beach, California. Mar Pollut Bull (2003) 0.98
Molecular mechanism of antitumor activity of taxanes in lung cancer (Review). Int J Oncol (2005) 0.97
Adenoviral delivery of A-FOS, an AP-1 dominant negative, selectively inhibits drug resistance in two human cancer cell lines. Cancer Gene Ther (2002) 0.97
Suramin's development: what did we learn? Invest New Drugs (2002) 0.97
ATM-dependent CHK2 activation induced by anticancer agent, irofulven. J Biol Chem (2004) 0.96
Thalidomide down-regulates the expression of VEGF and bFGF in cisplatin-resistant human lung carcinoma cells. Anticancer Res (2003) 0.96
Dopamine stimulation of postnatal murine subventricular zone neurogenesis via the D3 receptor. J Neurochem (2010) 0.95
Use of bacteriophage in the treatment of experimental animal bacteremia from imipenem-resistant Pseudomonas aeruginosa. Int J Mol Med (2006) 0.95
Detection of cyclin b1 expression in g(1)-phase cancer cell lines and cancer tissues by postsorting Western blot analysis. Cancer Res (2004) 0.95
Pharmacogenetic associations of CYP2C19 genotype with in vivo metabolisms and pharmacological effects of thalidomide. Cancer Biol Ther (2003) 0.95
Therapeutic effectiveness of bacteriophages in the rescue of mice with extended spectrum beta-lactamase-producing Escherichia coli bacteremia. Int J Mol Med (2006) 0.94
Hedgehog signaling pathway regulates the growth of ovarian cancer spheroid forming cells. Int J Oncol (2011) 0.94
Evaluation of cisplatin in combination with β-elemene as a regimen for prostate cancer chemotherapy. Basic Clin Pharmacol Toxicol (2010) 0.94
β-Elemene enhances susceptibility to cisplatin in resistant ovarian carcinoma cells via downregulation of ERCC-1 and XIAP and inactivation of JNK. Int J Oncol (2013) 0.94
The role of drugs and alcohol in rape. Med Sci Law (2006) 0.93
A fibronectin scaffold approach to bispecific inhibitors of epidermal growth factor receptor and insulin-like growth factor-I receptor. MAbs (2011) 0.92
Correlations among ERCC1, XPB, UBE2I, EGF, TAL2 and ILF3 revealed by gene signatures of histological subtypes of patients with epithelial ovarian cancer. Oncol Rep (2011) 0.91
BRCA1 contributes to cell cycle arrest and chemoresistance in response to the anticancer agent irofulven. Mol Pharmacol (2007) 0.91
SU5416 inhibited VEGF and HIF-1alpha expression through the PI3K/AKT/p70S6K1 signaling pathway. Biochem Biophys Res Commun (2004) 0.91
Diagnostic loop electrosurgical excisional procedure for discrepancy: do preoperative factors predict presence of significant cervical intraepithelial neoplasia? J Low Genit Tract Dis (2007) 0.90
Ethnic disparities in Americans of European descent versus Americans of African descent related to polymorphic ERCC1, ERCC2, XRCC1, and PARP1. Mol Cancer Ther (2008) 0.90
Cognitive functioning after radiotherapy or chemoradiotherapy for head-and-neck cancer. Int J Radiat Oncol Biol Phys (2010) 0.90
Selenium toxicity: a case of selenosis caused by a nutritional supplement. Ann Intern Med (2008) 0.89
MZF1 possesses a repressively regulatory function in ERCC1 expression. Biochem Pharmacol (2006) 0.88
β-elemene effectively suppresses the growth and survival of both platinum-sensitive and -resistant ovarian tumor cells. Anticancer Res (2012) 0.88
Contraceptive methods and risk of HIV acquisition or female-to-male transmission. Curr HIV/AIDS Rep (2014) 0.88
Endometrial cancer in women 45 years of age or younger: a clinicopathological analysis. Am J Obstet Gynecol (2005) 0.88
Protein phosphatase 2A interacts with Chk2 and regulates phosphorylation at Thr-68 after cisplatin treatment of human ovarian cancer cells. Int J Mol Med (2006) 0.88
ERCC1 measurements in clinical oncology. N Engl J Med (2006) 0.88
The ERCC1 N118N polymorphism does not change cellular ERCC1 protein expression or platinum sensitivity. Mutat Res (2011) 0.87
Inducible degradation of checkpoint kinase 2 links to cisplatin-induced resistance in ovarian cancer cells. Biochem Biophys Res Commun (2005) 0.87
The incidence and clinical significance of lymph node micrometastases determined by immunohistochemical staining in stage I - lymph node negative endometrial cancer. Histol Histopathol (2012) 0.87
Resources, roadblocks and turning points: a qualitative study of American Indian/Alaska Native adults with type 2 diabetes. J Community Health (2013) 0.87
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and its therapeutic potential in breast and gynecologic cancers. Gynecol Oncol (2007) 0.87
Effects of Kupffer cell inhibition on liver function and hepatocellular activity in mice. Int J Mol Med (2003) 0.87
Enhancement of cisplatin-induced apoptosis by β-elemene in resistant human ovarian cancer cells. Med Oncol (2013) 0.86
β-Elemene promotes cisplatin-induced cell death in human bladder cancer and other carcinomas. Anticancer Res (2013) 0.86
Genetic polymorphisms in XRCC1 associated with radiation therapy in prostate cancer. Cancer Biol Ther (2010) 0.86
A checklist designed to aid consistency and reproducibility of GRADE assessments: development and pilot validation. Syst Rev (2014) 0.86
Apoptosis in prostate cancer: progressive and therapeutic implications (Review). Int J Mol Med (2004) 0.86
Phase II trial of carboxyamidotriazole in patients with relapsed epithelial ovarian cancer. J Clin Oncol (2003) 0.86
Gleason score and pretreatment prostate-specific antigen in survival among patients with stage D2 prostate cancer. World J Urol (2004) 0.85
9-beta-D-arabinofuranosyl-2-fluoroadenine inhibits expression of vascular endothelial growth factor through hypoxia-inducible factor-1 in human ovarian cancer cells. Mol Pharmacol (2004) 0.85
Hydrodynamic pressure sensing with an artificial lateral line in steady and unsteady flows. Bioinspir Biomim (2012) 0.85
Changing stigma through a consumer-based stigma reduction program. Community Ment Health J (2013) 0.85
Fanconi anemia D2 protein confers chemoresistance in response to the anticancer agent, irofulven. Mol Cancer Ther (2006) 0.85
Mechanisms underlying the synergistic effect of SU5416 and cisplatin on cytotoxicity in human ovarian tumor cells. Int J Oncol (2004) 0.84
The role of an androgen receptor polymorphism in the clinical outcome of patients with metastatic prostate cancer. Urol Int (2002) 0.84
Reduced LIMK2 expression in colorectal cancer reflects its role in limiting stem cell proliferation. Gut (2013) 0.84
Epothilones: a novel class of non-taxane microtubule-stabilizing agents. Curr Pharm Des (2002) 0.84
Hysterectomy in women with cervical stenosis. Surgical indications and pathology. J Reprod Med (2003) 0.84
Sensitization of lung cancer cells to cisplatin by β-elemene is mediated through blockade of cell cycle progression: antitumor efficacies of β-elemene and its synthetic analogs. Med Oncol (2013) 0.83
Prioritizing treatment outcomes: head and neck cancer patients versus nonpatients. Head Neck (2004) 0.83
Public figure announcements about cancer and opportunities for cancer communication: a review and research agenda. Health Commun (2013) 0.83
A phase II study of irofulven in women with recurrent and heavily pretreated ovarian cancer. Gynecol Oncol (2005) 0.83
Retrospective analysis of weekly topotecan as salvage therapy in relapsed ovarian cancer. Gynecol Oncol (2004) 0.82
Subcellular localization of caspase-3 activation correlates with changes in apoptotic morphology in MOLT-4 leukemia cells exposed to X-ray irradiation. Int J Oncol (2005) 0.82
Double prophylaxis for deep venous thrombosis in patients with gynecologic oncology who are undergoing laparotomy: does preoperative anticoagulation matter? Int J Gynecol Cancer (2011) 0.81
Desmitis of the straight sesamoidean ligament in horses: 9 cases (1995-1997). J Am Vet Med Assoc (2003) 0.81
Development and characterization of five cell models for chemoresistance studies of human ovarian carcinoma. Int J Mol Med (2004) 0.81